Latest News

Adding targeted therapy drug to standard treatment benefits aggressive breast cancer patients

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

Source link

Related posts

New potential immunotherapy target in pancreatic cancer identified


New way to target cancer's diversity and evolution


COVID-19 outbreak likely to worsen in Brazil, says GlobalData


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World